Maxim Group set a $4.00 price objective on ContraVir Pharmaceuticals (NASDAQ:CTRV) in a research note released on Monday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Separately, ValuEngine raised ContraVir Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, February 2nd.
Shares of ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at $0.25 on Monday. The company has a market capitalization of $20.54, a price-to-earnings ratio of -0.51 and a beta of 1.79. ContraVir Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $1.96.
ContraVir Pharmaceuticals Company Profile
ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.
Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.